Zi‐Hao Chen
0000-0002-2575-0081
Publication & Citation Trends
Publications
0 total
Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients (pts) with chronic Phase-chronic myeloid leukemia (CP-CML)
Cited by 0
Semantic Scholar
Phase 1b/2 study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients (pts) with treatment-naïve (TN) or prior venetoclax (VEN)-exposed myeloid malignancies.
Cited by 1
Semantic Scholar
Results of POLARIS-1, a global Phase 3 study (Part A): Olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)
Cited by 0
Semantic Scholar
Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-Phase chronic myeloid leukemia (CML-CP) in a registrational randomized Phase 2 trial: Up to 4-year follow-up including patients without T315I mutat
Cited by 0
Semantic Scholar
Updated Results from a Phase 1b study of olverembatinib (HQP1351) combined with lisaftoclax (APG-2575) in pediatric patients with relapsed/refractory Philadelphia Chromosome–Positive acute lymphoblastic leukemia
Cited by 0
Semantic Scholar
Olverembatinib, a multikinase inhibitor that modulates lipid metabolism, in advanced succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 1b study and translational research
Cited by 4
Semantic Scholar
Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)
Cited by 0
Semantic Scholar
Results of the APG2575AU101 Study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients with newly diagnosed (ND) or prior venetoclax–exposed myeloid malignancies
Cited by 2
Semantic Scholar
Safety and efficacy of lisaftoclax, a novel BCL-2 inhibitor, in combination with azacitidine in patients with treatment-naïve or relapsed or refractory acute myeloid leukemia.
Cited by 2
Semantic Scholar
Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax
Cited by 5
Semantic Scholar
Research Topics
Spectroscopy and Quantum Chemical Studies
(20)
Quantum Information and Cryptography
(7)
Quantum and electron transport phenomena
(7)
Advanced Chemical Physics Studies
(5)
Advanced Thermodynamics and Statistical Mechanics
(5)
Affiliations
Agency for Science, Technology and Research
University of Science and Technology of China
Chinese Academy of Sciences
Guangxi Normal University
Wuhan University